ERBB2 and breast cancer: The RADHER trial overall showed successfully benefits as pre-operative treatment for HER-2+ breast cancer patients in terms of response rate [38], and combination of targeted therapies in this setting was not limited by toxicity (only 28.2% of patients in arm T+E had at least one side effect, 17.9% having a high-grade toxicity).